Evicenter
P&T meetings

Ivonescimab

EGFR-mutated non-small-cell lung cancer

Launch
Not announced
Last updated
79 sources

Clinical evidence

Case report: malignant pleural effusion and acquired complex resistance

6 evidence topics · 2 sources

Objective
Location and study date
Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using radiographic disease control as the reported outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

Not applicable.

Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This single-participant case cannot estimate a comparative treatment effect or establish that the reported resistance pattern predicts benefit. Disease control during monotherapy and subsequent combination treatment should not be conflated. The qualitative safety description does not provide an adverse-event rate.